Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H27N5O4 |
Molecular Weight | 437.4916 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CCCC[C@@]1([H])N(CCN2C(=O)C3=CC=CO3)C4=NC(N)=C5C=C(OC)C(OC)=CC5=N4
InChI
InChIKey=XBRXTUGRUXGBPX-DLBZAZTESA-N
InChI=1S/C23H27N5O4/c1-30-19-12-14-15(13-20(19)31-2)25-23(26-21(14)24)28-10-9-27(16-6-3-4-7-17(16)28)22(29)18-8-5-11-32-18/h5,8,11-13,16-17H,3-4,6-7,9-10H2,1-2H3,(H2,24,25,26)/t16-,17+/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/23767297Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18037913 | https://www.ncbi.nlm.nih.gov/pubmed/15598431
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23767297
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18037913 | https://www.ncbi.nlm.nih.gov/pubmed/15598431
CYCLAZOSIN HYDROCHLORIDE is a quinazoline derivative pharmacologically characterized as putative a1B-adrenoceptor antagonist.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL223 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17276073 |
3.24 nM [Ki] | ||
Target ID: CHEMBL229 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17276073 |
12.3 nM [Ki] | ||
Target ID: CHEMBL232 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17276073 |
0.135 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18037913
Male C-57 WT mice (22–35 g) were injected s.c. with the putative a1B-adrenoceptor antagonist cyclazosin (1.0mg/kg). Cyclazosin was administered 30 min prior to the injection of vehicle (1 ml/kg) or MDMA (20mg/kg). The putative a1B-adrenoceptor antagonist cyclazosin (1mg/kg) in vehicle experiments did not significantly alter the body temperature when compared to vehicle group. The pretreatment of mice with cyclazosin significantly altered the effect of MDMA on core body temperature
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23767297
Sections of the abdominal aorta, obtained from adult female New Zealand rabbits, were treated with agonists and antagonists of adrenergic receptors. Administration of cyclazosin at a dose of 0.002 μM caused a decrease in the muscle tonus of -0.49 ± 0.10 mN. After blockade of the α1B-adrenergic receptor by 0.02 mkM cyclazosin, the administration of 0.05 μM phenylephrine resulted in an increase of the aortic muscle tonus of 1.49 ± 0.14 mN.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
132266
Created by
admin on Sat Dec 16 09:03:54 GMT 2023 , Edited by admin on Sat Dec 16 09:03:54 GMT 2023
|
PRIMARY | |||
|
63937
Created by
admin on Sat Dec 16 09:03:54 GMT 2023 , Edited by admin on Sat Dec 16 09:03:54 GMT 2023
|
PRIMARY | |||
|
DTXSID701112809
Created by
admin on Sat Dec 16 09:03:54 GMT 2023 , Edited by admin on Sat Dec 16 09:03:54 GMT 2023
|
PRIMARY | |||
|
2FH26454WF
Created by
admin on Sat Dec 16 09:03:54 GMT 2023 , Edited by admin on Sat Dec 16 09:03:54 GMT 2023
|
PRIMARY | |||
|
210542-51-1
Created by
admin on Sat Dec 16 09:03:54 GMT 2023 , Edited by admin on Sat Dec 16 09:03:54 GMT 2023
|
PRIMARY |
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD